JP2012125257A5 - - Google Patents

Download PDF

Info

Publication number
JP2012125257A5
JP2012125257A5 JP2012077593A JP2012077593A JP2012125257A5 JP 2012125257 A5 JP2012125257 A5 JP 2012125257A5 JP 2012077593 A JP2012077593 A JP 2012077593A JP 2012077593 A JP2012077593 A JP 2012077593A JP 2012125257 A5 JP2012125257 A5 JP 2012125257A5
Authority
JP
Japan
Prior art keywords
virus
ribozyme
microorganism
composition
indicator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012077593A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012125257A (ja
JP5615865B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012125257A publication Critical patent/JP2012125257A/ja
Publication of JP2012125257A5 publication Critical patent/JP2012125257A5/ja
Application granted granted Critical
Publication of JP5615865B2 publication Critical patent/JP5615865B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2012077593A 2002-02-28 2012-03-29 外来性の物質の検出におけるリボザイムの使用 Expired - Lifetime JP5615865B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36073002P 2002-02-28 2002-02-28
US60/360,730 2002-02-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2008235697A Division JP2009005712A (ja) 2002-02-28 2008-09-12 外来性の物質の検出におけるリボザイムの使用

Publications (3)

Publication Number Publication Date
JP2012125257A JP2012125257A (ja) 2012-07-05
JP2012125257A5 true JP2012125257A5 (https=) 2013-06-20
JP5615865B2 JP5615865B2 (ja) 2014-10-29

Family

ID=27766245

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2003571491A Expired - Fee Related JP4369243B2 (ja) 2002-02-28 2003-02-26 外来性の物質の検出におけるリボザイムの使用
JP2008235697A Withdrawn JP2009005712A (ja) 2002-02-28 2008-09-12 外来性の物質の検出におけるリボザイムの使用
JP2012077593A Expired - Lifetime JP5615865B2 (ja) 2002-02-28 2012-03-29 外来性の物質の検出におけるリボザイムの使用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2003571491A Expired - Fee Related JP4369243B2 (ja) 2002-02-28 2003-02-26 外来性の物質の検出におけるリボザイムの使用
JP2008235697A Withdrawn JP2009005712A (ja) 2002-02-28 2008-09-12 外来性の物質の検出におけるリボザイムの使用

Country Status (16)

Country Link
EP (2) EP1481084B1 (https=)
JP (3) JP4369243B2 (https=)
AR (1) AR038849A1 (https=)
AT (1) ATE519860T1 (https=)
AU (1) AU2003206587B2 (https=)
BR (1) BR0307882A (https=)
CA (1) CA2374388C (https=)
DE (1) DE03704136T1 (https=)
DK (1) DK1481084T3 (https=)
ES (1) ES2241506T3 (https=)
MX (1) MXPA04008277A (https=)
NZ (1) NZ534488A (https=)
TR (1) TR200501513T3 (https=)
TW (1) TWI329132B (https=)
WO (1) WO2003072811A2 (https=)
ZA (1) ZA200406231B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1306959C (zh) * 2004-09-21 2007-03-28 中国科学院武汉病毒研究所 草鱼呼肠孤病毒抗原亚单位疫苗制备方法
US10260049B2 (en) 2005-08-01 2019-04-16 Virocure, Inc. Attenuated reovirus
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
TW201738562A (zh) * 2009-05-28 2017-11-01 亞培生物股份有限公司 體外病原體檢驗技術

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5254678A (en) 1987-12-15 1993-10-19 Gene Shears Pty. Limited Ribozymes
US5168053A (en) 1989-03-24 1992-12-01 Yale University Cleavage of targeted RNA by RNAase P
US5225337A (en) 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Ribozyme compositions and methods for use
US5225347A (en) 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Therapeutic ribozyme compositions and expression vectors
AU672018B2 (en) 1992-07-02 1996-09-19 Sankyo Company Limited Looped, hairpin ribozyme
WO1994013791A1 (en) * 1992-12-04 1994-06-23 Innovir Laboratories, Inc. Regulatable nucleic acid therapeutic and methods of use thereof
ATE178490T1 (de) 1993-02-16 1999-04-15 Onyx Pharmaceuticals Cytopathische viren zur therapie und prophylaxe der neoplasie
CA2161671A1 (en) 1993-04-30 1994-11-10 Robert M. Lorence Methods of treating and detecting cancer using viruses
WO1995010608A1 (en) * 1993-10-15 1995-04-20 Foundation For Research And Technology - Hellas (Fo.R.T.H.) Asymmetric hammerhead ribozymes and nucleotide sequences for their construction
US5631359A (en) 1994-10-11 1997-05-20 Ribozyme Pharmaceuticals, Inc. Hairpin ribozymes
US6107027A (en) * 1994-12-14 2000-08-22 University Of Washington Ribozymes for treating hepatitis C
US6136307A (en) 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
CN101618049A (zh) 1997-10-09 2010-01-06 威尔斯塔特生物公司 使用病毒来治疗赘生物
US6307041B1 (en) 1998-03-28 2001-10-23 University Of Utah Research Foundation Circular, hairpin, circular/hairpin, lariat, and hairpin-lariat hammerhead ribozymes
AU6522599A (en) * 1998-10-23 2000-05-15 Children's Medical Center Corporation Use of a self-cleaving rna motif to modulate gene expression
US7122645B2 (en) * 2000-03-27 2006-10-17 Smithkline Beecham Corporation Detection of viable agents
TWI289158B (en) 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus

Similar Documents

Publication Publication Date Title
Mishra et al. The interplay between viral-derived miRNAs and host immunity during infection
Vojtechova et al. The role of miRNAs in virus-mediated oncogenesis
Bernier et al. The diverse roles of microRNAs at the host–virus interface
Morales et al. SARS-CoV-encoded small RNAs contribute to infection-associated lung pathology
Sun et al. Comparative transcriptome analysis reveals the intensive early stage responses of host cells to SARS-CoV-2 infection
Huang et al. Establishment of a reverse genetics system for studying human bocavirus in human airway epithelia
Zheng et al. Human microRNA hsa-miR-296-5p suppresses enterovirus 71 replication by targeting the viral genome
Gao et al. The influenza A virus PB2, PA, NP, and M segments play a pivotal role during genome packaging
Xue et al. Propagation and characterization of influenza virus stocks that lack high levels of defective viral genomes and hemagglutinin mutations
Devignot et al. A virus-like particle system identifies the endonuclease domain of Crimean-Congo hemorrhagic fever virus
Meyer et al. Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses
Sajid et al. siRNA Therapeutics for the Therapy of COVID-19 and Other Coronaviruses
Thornburg et al. Respiratory syncytial virus regulates human microRNAs by using mechanisms involving beta interferon and NF-κB
Vázquez-Calvo et al. Acid-dependent viral entry
Rogee et al. New models of hepatitis E virus replication in human and porcine hepatocyte cell lines
Hamelin et al. Oseltamivir-resistant pandemic A/H1N1 virus is as virulent as its wild-type counterpart in mice and ferrets
Krähling et al. Establishment of fruit bat cells (Rousettus aegyptiacus) as a model system for the investigation of filoviral infection
Ruan et al. Human early syncytiotrophoblasts are highly susceptible to SARS-CoV-2 infection
JP2012125257A5 (https=)
Xue et al. Viral RNA N 6-methyladenosine modification modulates both innate and adaptive immune responses of human respiratory syncytial virus
Pratelli et al. Role of the lipid rafts in the life cycle of canine coronavirus
JP2016533172A5 (https=)
Hoffmann et al. The hemagglutinin of bat-associated influenza viruses is activated by TMPRSS2 for pH-dependent entry into bat but not human cells
Masic et al. An eight-segment swine influenza virus harboring H1 and H3 hemagglutinins is attenuated and protective against H1N1 and H3N2 subtypes in pigs
Aerts et al. Effect of in vitro syncytium formation on the severity of human metapneumovirus disease in a murine model